Hyperuricemia, gout and comorbidity
Hyperuricemia is most often combined with lipid metabolism disorders, modifiable risk factors for coronary heart disease, stroke, abdominal obesity, type 2 diabetes mellitus, arterial hypertension, urolithiasis, chronic kidney disease. Current data indicate the presence of pro-inflammatory, pro-oxid...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2023-01-01
|
| Series: | Klinicist |
| Subjects: | |
| Online Access: | https://klinitsist.abvpress.ru/Klin/article/view/511 |
| _version_ | 1826546527998312448 |
|---|---|
| author | N. A. Shostak N. G. Pravdyuk T. K. Loginova G. N. Lazarenko |
| author_facet | N. A. Shostak N. G. Pravdyuk T. K. Loginova G. N. Lazarenko |
| author_sort | N. A. Shostak |
| collection | DOAJ |
| description | Hyperuricemia is most often combined with lipid metabolism disorders, modifiable risk factors for coronary heart disease, stroke, abdominal obesity, type 2 diabetes mellitus, arterial hypertension, urolithiasis, chronic kidney disease. Current data indicate the presence of pro-inflammatory, pro-oxidant and vasoconstrictive effects of uric acid, which may contribute to the development of cardiometabolic disorders. Normal serum uric acid levels are <6 mg / dl (<360 mmol / l) for women and <7 mg / dl (<420 mmol / l) for men. Currently, the role of hyperuricemia as an independent biomarker of the risk of cardiovascular events is emphasized. Both gout and subclinical hyperuricemia are associated with unfavorable cardiovascular outcomes. Patients should be informed about the risk factors of hyperuricemia; the need for lifestyle modification, diet compliance, and correction of drug therapy for comorbid conditions. According to international and domestic recommendations, urate-lowering therapy is indicated for asymptomatic hyperuricemia (>360 mmol / l) and high cardiovascular risk. The data available today allow us to consider the target serum uric acid level <5 mg / dl (<300 mmol / l) for patients with high cardiovascular risk, including at least 2 of the following risk factors: hypertension, diabetes mellitus, dyslipidemia, stroke, heart attack, chronic disease kidneys, and <6 mg / dl for patients who do not have these risk factors. The urate-lowering drug is selected taking into account the concomitant pathology and the presence or absence of liver or kidney dysfunction. Xanthine oxidase inhibitors are still the first-line drugs for the correction of hyperuricemia. The superiority of xanthine oxidase inhibitors is due to the potential inhibition of the production of reactive oxygen species and their antioxidant effect. Treatment of gout is aimed at achieving clinical improvement in acute and chronic arthritis, preventing recurrence of arthritis and damage to internal organs, as well as reducing the risks of negative effects on comorbid pathology. Clinicians are faced with the task of controlling cardiovascular diseases in patients with asymptomatic hyperuricemia and gout. Further studies are needed to investigate the relationship between gout, hyperuricemia and increased risk of cardiovascular diseases, as well as to establish a more complete picture of the prevalence of a wide range of comorbid conditions. |
| first_indexed | 2024-04-09T20:26:18Z |
| format | Article |
| id | doaj.art-1e19ef6df6a142bbab05a1aba81e0b3f |
| institution | Directory Open Access Journal |
| issn | 1818-8338 |
| language | Russian |
| last_indexed | 2025-03-14T05:35:11Z |
| publishDate | 2023-01-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Klinicist |
| spelling | doaj.art-1e19ef6df6a142bbab05a1aba81e0b3f2025-03-05T14:05:13ZrusABV-pressKlinicist1818-83382023-01-01163586410.17650/1818-8338-2022-16-3-K648390Hyperuricemia, gout and comorbidityN. A. Shostak0N. G. Pravdyuk1T. K. Loginova2G. N. Lazarenko3Acad. A.I. Nesterov of Faculty Therapy, N.I. Pirogov Russian National Research Medical University (Pirogov Medical University) of the Ministry of Health of RussiaAcad. A.I. Nesterov of Faculty Therapy, N.I. Pirogov Russian National Research Medical University (Pirogov Medical University) of the Ministry of Health of RussiaAcad. A.I. Nesterov of Faculty Therapy, N.I. Pirogov Russian National Research Medical University (Pirogov Medical University) of the Ministry of Health of RussiaFederal center of brain research and neurotechnologies of the Federal Medical Biological AgencyHyperuricemia is most often combined with lipid metabolism disorders, modifiable risk factors for coronary heart disease, stroke, abdominal obesity, type 2 diabetes mellitus, arterial hypertension, urolithiasis, chronic kidney disease. Current data indicate the presence of pro-inflammatory, pro-oxidant and vasoconstrictive effects of uric acid, which may contribute to the development of cardiometabolic disorders. Normal serum uric acid levels are <6 mg / dl (<360 mmol / l) for women and <7 mg / dl (<420 mmol / l) for men. Currently, the role of hyperuricemia as an independent biomarker of the risk of cardiovascular events is emphasized. Both gout and subclinical hyperuricemia are associated with unfavorable cardiovascular outcomes. Patients should be informed about the risk factors of hyperuricemia; the need for lifestyle modification, diet compliance, and correction of drug therapy for comorbid conditions. According to international and domestic recommendations, urate-lowering therapy is indicated for asymptomatic hyperuricemia (>360 mmol / l) and high cardiovascular risk. The data available today allow us to consider the target serum uric acid level <5 mg / dl (<300 mmol / l) for patients with high cardiovascular risk, including at least 2 of the following risk factors: hypertension, diabetes mellitus, dyslipidemia, stroke, heart attack, chronic disease kidneys, and <6 mg / dl for patients who do not have these risk factors. The urate-lowering drug is selected taking into account the concomitant pathology and the presence or absence of liver or kidney dysfunction. Xanthine oxidase inhibitors are still the first-line drugs for the correction of hyperuricemia. The superiority of xanthine oxidase inhibitors is due to the potential inhibition of the production of reactive oxygen species and their antioxidant effect. Treatment of gout is aimed at achieving clinical improvement in acute and chronic arthritis, preventing recurrence of arthritis and damage to internal organs, as well as reducing the risks of negative effects on comorbid pathology. Clinicians are faced with the task of controlling cardiovascular diseases in patients with asymptomatic hyperuricemia and gout. Further studies are needed to investigate the relationship between gout, hyperuricemia and increased risk of cardiovascular diseases, as well as to establish a more complete picture of the prevalence of a wide range of comorbid conditions.https://klinitsist.abvpress.ru/Klin/article/view/511hyperuricemiagoutcomorbiditycardiovascular riskuric acidhypertensionabdominal obesitydiabetes mellitusmyocardial infarctionheart failurechronic kidney diseaseallopurinolfebuxostatcolchicine |
| spellingShingle | N. A. Shostak N. G. Pravdyuk T. K. Loginova G. N. Lazarenko Hyperuricemia, gout and comorbidity Klinicist hyperuricemia gout comorbidity cardiovascular risk uric acid hypertension abdominal obesity diabetes mellitus myocardial infarction heart failure chronic kidney disease allopurinol febuxostat colchicine |
| title | Hyperuricemia, gout and comorbidity |
| title_full | Hyperuricemia, gout and comorbidity |
| title_fullStr | Hyperuricemia, gout and comorbidity |
| title_full_unstemmed | Hyperuricemia, gout and comorbidity |
| title_short | Hyperuricemia, gout and comorbidity |
| title_sort | hyperuricemia gout and comorbidity |
| topic | hyperuricemia gout comorbidity cardiovascular risk uric acid hypertension abdominal obesity diabetes mellitus myocardial infarction heart failure chronic kidney disease allopurinol febuxostat colchicine |
| url | https://klinitsist.abvpress.ru/Klin/article/view/511 |
| work_keys_str_mv | AT nashostak hyperuricemiagoutandcomorbidity AT ngpravdyuk hyperuricemiagoutandcomorbidity AT tkloginova hyperuricemiagoutandcomorbidity AT gnlazarenko hyperuricemiagoutandcomorbidity |